Benitec Biopharma

    [td_text_with_title custom_title=”Company description”]Benitec Biopharma has developed a breakthrough platform — ddRNAi — for treating human diseases.

    Unlike other RNAi-based technologies, ddRNAi effects lasting change in target cells, leading to long term benefit and potentially cure.[/td_text_with_title]

    [td_text_with_title custom_title=”Latest post”]

    Benitec Biopharma sets price at 13-13.06 $

    Benitec Biopharma, which is developing gene therapies for hepatitis C based on RNA interference, announced terms for its IPO on Monday. The Balmain, Australia-based company plans to raise $65 million by offering 5 million shares at a price range of $13.06 to $13.06. At the midpoint of the proposed range, Benitec Biopharma would valued at $141 […]


    Benitec Biopharma files for a $70 million US IPO

    Benitec Biopharma, which is developing gene therapies for hepatitis C based on RNA interference, filed on Monday with the SEC to raise up to $70 million in an initial public offering. The company’s stock currently trades on the Australian Securities Exchange under the symbol BLT. The Balmain, Australia-based company, which was founded in 1995, plans […]

    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Benitec Biopharma Ltd ASXBLT is an Australian biotechnology company founded in 1997.[2] It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.[3]

    The Commonwealth Scientific and Industrial Research Organisation (CSIRO) has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.[4]

    Partnerships and Collaborations

    Benitec Biopharma and its subsidiary Tacere Therapeutics has partnerships with:[1][3][5]

    Research and Development

    Benitec Biopharma and its partners and licensees are researching ddRNAi in the following fields:


    1. ^ a b c d e f g h i j k l "Benitec Biopharma Annual Report 2013" (PDF). Benitec. Retrieved 16 January 2014. [permanent dead link]
    2. ^ "Australian Securities Exchange". ASX. Retrieved 11 April 2012. 
    3. ^ a b "GlobalData Financial and Strategic SWOT Analysis Review". GlobalData. Archived from the original on 24 January 2013. Retrieved 11 April 2012. 
    4. ^ "Licensing RNAi gene technology. CSIRO. 14 Oct 2011". CSIRO. Archived from the original on 18 May 2012. Retrieved 12 April 2012. 
    5. ^ "Australian Life Scientist. CSIRO, Benitec strengthen RNAi patent positions. 24 October 2005". Australian Life Scientist. Archived from the original on 15 October 2009. Retrieved 12 April 2012. 
    6. ^ "Clinical Trial NCT01899092". US National Institute of Health. Retrieved 16 January 2014. 
    7. ^ "Biomics Biotechnologies – Pipeline". Biomics Biotechnologies. Retrieved 21 January 2014. 
    8. ^ "Clinical Trial NCT01734850". US National Institute of Health. Retrieved 16 January 2014. 
    9. ^ a b "Bioshares Edition 434. 25 November 2011" (PDF). Bioshares. Retrieved 21 January 2014. 
    10. ^ a b "Benitec Biopharma Annual Report 2012" (PDF). Benitec. Retrieved 16 January 2014. 
    11. ^ "Cancer Collaboration. 10 May 2011". UNSW Australia. Retrieved 21 January 2014. 
    12. ^ "Benitec Biopharma Annual Report 2011" (PDF). Benitec. Retrieved 16 January 2014. 
    13. ^ "Genable Receives $6.8 Million Investment to Develop Gene Therapy for Dominant RP". Foundation Fighting Blindness. Retrieved 16 January 2014. 
    14. ^ "uniQure licenses RNA interference technology to advance Huntington's disease program". PR Newswire. Retrieved 21 January 2014.